尊龙凯时·人生就是搏(中国区)官方网站

Recently, the Department of Industry and Information Technology of Shandong Province and Jinan Municipal Federation of Trade Unions announced that Kexing Biopharm had been awarded the title of "All-involvement Innovation Enterprise in Jinan City". In addition, our major product Human Erythropoietin (EPOSINO) was recognized as the "Champion Project of Manufacturing Industry in Shandong Province", indicating that our innovation-driven development strategy already has achieved initial results.

Building an innovation platform to promote all-involvement innovation

We advocate the culture of innovation and the concept of all-involvement innovation, so as to stimulate the innovation enthusiasm and vitality of our employees. As an innovative biologics manufacturer, we have adhered to innovation-driven development ever since our establishment. After our listing on the Sci-Tech Innovation Board on December 14, 2020, our awareness of scientific and technological innovation was further enhanced and it has now become the company's doctrine and belief. We have always focused on solving unmet clinical needs and through "scientific and technological innovation", we strive to achieve product innovation and upgrading, keep pace with the times in terms of management, and continuously optimize our organization. Finally, we will conquer refractory diseases and protect human health through "human-oriented innovation".

With over two decades of experience in the business, we have established a complete system of pharmaceutical R&D and innovation, covering pharmaceutical innovation from pharmaceutical discovery, pharmaceutical research, preclinical research, and clinical research to industrialized production. With the help of prokaryotic cell technology, eukaryotic cell technology and viable bacteria technology, we have built five world-leading technology platforms, namely a strain platform, a recombinant protein therapeutics industrialization platform, a microecologics R&D and industrialization platform, a recombinant protein secretion and expression platform and a long-acting recombinant protein platform.

Our R&D team composed of nearly 180 members from various fields including molecular biology, pharmacy, and pharmaceutics, with a team of core technicians that have all worked with R&D for more than 10 years. We have obtained 39 patents, and we have nine biopharmaceuticals under research, including three new biopharmaceuticals. Furthermore, our R&D innovation capacity and technical capacity have been widely recognized and we have been awarded honors such as "Shandong Provincial Enterprise Technology Center" in 2017, "Jinan Protein Drug Engineering Laboratory" in 2018, as well as "Guangdong Recombinant Protein Therapeutics Engineering Technology Center", "Shandong Protein Drug Engineering Laboratory" and "Shenzhen Postdoctoral Innovative Practice Base" in 2020.

Exploring major products to claim the title of Champion

Recently, according to the List of the Fifth Batch of Champion Enterprises and Champion Products in Manufacturing Industry of Shandong Province published by the Department of Industry and Information Technology of Shandong Province, Human Erythropoietin (EPOSINO) was identified as the Champion Product of the Manufacturing Industry in Shandong Province. This award is given to a company that has a leading position in production technology and the production process, attaches importance to R&D investment, and has independent intellectual property rights and high-quality products, with key performance indicators exceeding those of similar companies in China. The winner must also have a market share among the top 5 in China and the biggest market share within its province.

With over two decades of experience in the industrialized production of biopharmaceuticals, we have taken the lead in production technology and process, been certified by Brazil's ANVISA GMP, and obtained product registration from more than 30 countries and regions, while our quality system has been recognized worldwide. We attach great importance to drug R&D and in recent years, we have continuously increased our R&D investment. We have 39 independent intellectual property rights. EPOSINO is the first human erythropoietin approved for R&D in China. It is also the first to obtain a new drug certificate and official approval and the first to use prefilled syringes in China. Since its launch, EPOSINO has been recognized by a majority of doctors and patients for its efficacy and safety. It has been sold all over China, with the third biggest market share in China and the biggest in Shandong Province. Besides, it has been exported to more than 30 countries and regions, including Brazil, the Philippines, and Indonesia.

Staying true to technology innovation and serving patients worldwide

We will continue with our mission of "Precise Products, Predictable Effects and Health Protection", adhere to technology innovation, and focus on our development strategy for biopharmaceuticals. Based on recombinant proteins and micro-ecological agents, we will build up cutting-edge biotechnology platforms for new proteins, new antibodies, and nucleic acid drugs, becoming a leader in high-quality biologicals and benefiting patients all over the world.